Schedule 13D ownership disclosure

NovaBay Pharmaceuticals Inc

Common Stock, $0.01 par value · CUSIP: 66987P409

Event date: 2025-10-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Framework Ventures IV L.P.Reported CIK 0002028474

    Shares: 1,164,117.00 · Class: 16.2%

  • Framework Ventures Management LLC

    Shares: 1,164,117.00 · Class: 16.2%

  • Framework Ventures IV GP LLC

    Shares: 1,164,117.00 · Class: 16.2%

  • Vance Spencer

    Shares: 1,164,117.00 · Class: 16.2%

  • Michael Ernest Anderson

    Shares: 1,164,117.00 · Class: 16.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001829126-25-008155
Form type
SCHEDULE 13D
Filer
Framework Ventures IV L.P.
CIK
CIK 2028474
Filed
Oct 15, 2025
Reporting period
Oct 09, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub